Sugi Predict

Sugi Predict / Compounds / SCHEMBL4487068

SCHEMBL4487068

SCHEMBL4487068

CC(C)(C)OC(=O)Nc1cccc2c1OCO2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.49
▸ HPGD P15428 2/20 0.49
▸ POLB P06746 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ ACVRL1 P37023 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.41
▸ ABCB1 P08183 1/20 0.41
▸ FLT1 P17948 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ BRD9 Q9H8M2 1/20 0.40
▸ DRD2 P14416 3/20 0.39
▸ HTR2A P28223 3/20 0.39
▸ DRD3 P35462 3/20 0.39
▸ METAP1 P53582 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.38
▸ BCL2 P10415 1/20 0.37
▸ BECN1 Q14457 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30317135 0.89 MRGPRX1 (0.46) KDM4EMAPK1ALDH1A1RXFP1ABCB1
SCHEMBL7949833 0.89 MRGPRX1 (0.46) KDM4EMAPK1ALDH1A1RXFP1ABCB1
SCHEMBL14115513 0.82 ALDH1A1 (0.42) KDM4EHPGDPOLBLMNAMAPK1
SCHEMBL3549192 0.81 NPC1 (0.41) KDM4EHPGDACVRL1NPC1RAB9A
SCHEMBL7846620 0.80 NPC1 (0.41) KDM4EHPGDLMNAMAPK1ALDH1A1
SCHEMBL6814622 0.80 NPC1 (0.45) HPGDPOLBALDH1A1RXFP1ABCB1
SCHEMBL10170103 0.80 ALDH1A1 (0.48) KDM4EHPGDPOLBLMNAMAPK1
SCHEMBL6316842 0.79 LMNA (0.56) KDM4EHPGDPOLBLMNAMAPK1
SCHEMBL1171855 0.79 KDM4E (0.45) KDM4EHPGDPOLBLMNAALDH1A1
SCHEMBL26148249 0.79 CA12 (0.40) KDM4EHPGDPOLBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-10-12 — — US disclosed
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-10-12 — — US disclosed
EP-4219485-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-02 — — EP disclosed
WO-2023092175-A1 NOVEL P2X7 RECEPTOR ANTAGONISTS THE UNIVERSITY OF SYDNEY (AU) 2023-06-01 — — WO disclosed
US-20120269769-A1 Hepatitis C Inhibitor Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-25 — — US disclosed
US-20120034187-A1 Hepatitis C Inhibitor Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-09 — — US disclosed
US-8067438-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-29 — — US disclosed
US-20110177030-A1 Hepatitis C Inhibitor Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-21 — — US disclosed
US-7939667-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 — — US disclosed
US-7939667-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-10 — — US disclosed
EP-1453492-A2 USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES Astrazeneca AB (SE) 2004-09-08 — — EP disclosed
EP-1409481-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS Astrazeneca AB (SE) 2004-04-21 — — EP disclosed
US-20040034046-A1 Quinazoline derivatives ASTRAZENECA AB (SE) 2004-02-19 — — US disclosed
WO-2004004732-A1 QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-01-15 — — WO disclosed
WO-2004005284-A1 SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS ASTRAZENECA AB (SE) 2004-01-15 — — WO disclosed
WO-2003047582-A1 QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS ASTRAZENECA AB (SE) 2003-06-12 — — WO disclosed
WO-2003045364-A2 USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-06-05 — — WO disclosed
EP-1313727-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2003-05-28 — — EP disclosed
WO-2003008409-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2003-01-30 — — WO disclosed
WO-2002016352-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120269769-A1 Hepatitis C Inhibitor Compounds HAVCR2, CTRL, CTRC KDM4E 3536/4885HPGD 2635/4885POLB 3280/4885
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CYP3A43, ABCB1, ABCB11 KDM4E 4471/4885HPGD 751/4885POLB 3874/4885
US-20120034187-A1 Hepatitis C Inhibitor Compounds HAVCR2, CTRL, CTRC KDM4E 3536/4885HPGD 2635/4885POLB 3280/4885
US-20110177030-A1 Hepatitis C Inhibitor Compounds HAVCR2, CTRL, CTRC KDM4E 3536/4885HPGD 2635/4885POLB 3280/4885
US-20040034046-A1 Quinazoline derivatives NQO2, NRAS, TOP1 KDM4E 3684/4885HPGD 553/4885POLB 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.